Publications

Abstract
Background: Small-bowel adenocarcinoma (SBA) is a rare malignancy with limited knowledge of the molecular mechanisms or clinical evidence-based guidelines for therapy. We conducted a comprehensive analysis of biomarkers with therapeutic relevance for SBA.